Chukyo Iyakuhin Co., Ltd. (4558) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Chukyo Iyakuhin Co., Ltd. (4558:JPX), powered by AI.

Current Price
¥199
P/E Ratio
47.0
Market Cap
2.1B
Sector
Consumer Cyclical
What is the Chukyo Iyakuhin Co., Ltd. stock price forecast?

Chukyo Iyakuhin Co., Ltd. is currently trading at ¥199. View real-time AI analysis on Alpha Lenz.

What is Chukyo Iyakuhin Co., Ltd. insider trading activity?

View the latest insider trading data for Chukyo Iyakuhin Co., Ltd. on Alpha Lenz.

What is Chukyo Iyakuhin Co., Ltd.'s P/E ratio?

Chukyo Iyakuhin Co., Ltd.'s P/E ratio is 47.0.

Chukyo Iyakuhin Co., Ltd.

JPX · 4558
¥199+1(+0.51%)Market closedJPX regular session 09:00–15:00 JST
Ask about Chukyo Iyakuhin Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Chukyo Iyakuhin Co., Ltd. trades at a P/E of 47.0 (premium valuation) with modest ROE of 1.8%.

Ask for details

Company Overview

Chukyo Iyakuhin Co., Ltd. is a pharmaceutical company based in Japan, primarily engaged in the development, production, and distribution of pharmaceutical products. Its primary function is to provide healthcare solutions through a diverse portfolio of medications that address various medical needs. The company focuses on producing ethical pharmaceuticals, including prescription drugs, which are used to treat chronic and acute illnesses. Additionally, Chukyo Iyakuhin Co., Ltd. manufactures over-the-counter medicines, catering to a wide range of common health concerns. Chukyo Iyakuhin Co., Ltd. plays a significant role in the healthcare industry, both domestically and internationally, by ensuring the availability of essential medications and contributing to the advancement of medical treatments. Its products are integral to hospitals, clinics, and pharmacies, highlighting its importance in the global supply chain of pharmaceutical goods. The company is also involved in research and development to foster innovation, aiming to improve healthcare outcomes through new drug discoveries. Overall, Chukyo Iyakuhin Co., Ltd. is a key player in the pharmaceutical market, addressing patient needs and supporting healthcare systems with a strong commitment to quality and efficacy.

CEOMr. Shuji Yonezu
SectorConsumer Cyclical
IndustryDepartment Stores
Employees607

Company Statistics

FY 2025

Profile

¥2,120,146,000Market Cap
¥6,306,646,000Revenue
0.00Shares Out
607Employees

Margins

57.80%Gross
3.56%EBITDA
1.68%Operating
1.99%Pre-Tax
0.72%Net

Valuation

46.96P/E
0.84P/B
0.34EV/Sales
9.78EV/EBITDA
347.56P/FCF

Growth (CAGR)

5.60%Rev 3Yr
4.07%Rev 5Yr
18.13%Op Inc 3Yr
8.29%Op Inc 5Yr
10.77%Net Inc 3Yr
35.06%Net Inc 5Yr

Returns

0.89%ROA
1.79%ROE
2.65%ROIC

Financial Health

¥1,235,465,000Cash & Cash Equivalents
¥1,303,683,000Net Debt
100.52%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Chukyo Iyakuhin Co., Ltd. (ticker: 4558) is a company listed on JPX in the Consumer Cyclical sector (Department Stores). It has approximately 607 employees. Market cap is $2.1B.

The current price is 199 with a P/E ratio of 46.96x and P/B of 0.84x.

ROE is 1.79% and operating margin is 1.68%. Annual revenue is $6.3B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Chukyo Iyakuhin Co., Ltd. (4558) Stock Forecast 2026 ¥199 — Price, Financials & Analyst Targets | Alpha Lenz